Failure-mode evidence depth
Coverage meters, not risk scores. Open the linked section to read direction.Stack
Reviewed sequence, HELM, or SMILES representation used to interpret this peptide identity.
Molecular graph, chemical representation, 3D references, and covalent topology when available.
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity.
Product-level route, label, and clinical context that frames peptide-level evidence.
What evidence describes systemic exposure or absorption?
What is known about distribution, binding, permeability, or barrier crossing?
What evidence describes clearance or persistence?
Cross-domain evidence distribution, traceability, and measurement-level detail for this peptide.
Reference-level support for checking reported names, sequence notation, and peptide identity agreement.
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Are molecular graph, topology, or 3D coordinates available?
Can basic developability descriptors be computed?
How stable is the peptide in biological matrices or protease systems?
What safety, toxicity, or tolerability evidence is attached?
Not availablePolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.
No disulfide, staple, coordination, other cross-link, or residue-level modification annotation is attached to this peptide in the current release.
Interpretation: A 2D graph describes connectivity, not conformation. A 3D reference describes one coordinate model or solved state, not the full ensemble. ADMET interpretation should account for peptidoform, topology, and assay context together.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Bioavailability, AUC, Cmax, and Tmax evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 78.4 % | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Lanreotide· 12.3 Pharmacokinetics · lanreotide bioavailability 120mg · After a single, de... | Open |
| 2 | 73.4 % | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Lanreotide· 12.3 Pharmacokinetics · lanreotide bioavailability 60mg · After a single, dee... | Open |
| 3 | 69 % | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Lanreotide· 12.3 Pharmacokinetics · lanreotide bioavailability 90mg · After a single, dee... | Open |
| 4 | Observation Lanreotide forms a drug depot at the site of injection; therefore, there are 2 phases that describe the absorption of Lanreotide: 1. Initial rapid subcutaneous release during the first few days of treatment where drug that has not precipitated is rapidly absorbed. 2. Slow release of drug from the depot via passive diffusion. Absorption is independent of body weight, gender, and dosage. | Reported | PepTherDia curated product PK field | Route: SC · 40 · Lanreotide · exact product name match · field mismatch | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | Observation Single-dose linearity was demonstrated with respect to AUC and C max , and showed high inter-subject variability. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Lanreotide· 12.3 Pharmacokinetics · cmax auc single dose linearity variability text · Sin... | Open |
| 2 | Observation An approximate 2-fold decrease in total serum clearance of lanreotide, with a consequent 2-fold increase in half-life and AUC was observed. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · serum | Lanreotide· 12.3 Pharmacokinetics · lanreotide renal impairment auc change text · An appr... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 4.3-8.4 ng/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Lanreotide· 12.3 Pharmacokinetics · cmax mean range · Mean C max values ranged from 4.3 t... | Open |
| 2 | 7.7 ng/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Lanreotide· 12.3 Pharmacokinetics · lanreotide steady state cmax 120mg · At steady state,... | Open |
| 3 | 3.8 ng/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Lanreotide· 12.3 Pharmacokinetics · lanreotide steady state cmax 60mg · At steady state,... | Open |
| 4 | 5.7 ng/mL | Comparable | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Lanreotide· 12.3 Pharmacokinetics · lanreotide steady state cmax 90mg · At steady state,... | Open |
| 5 | Observation Single-dose linearity was demonstrated with respect to AUC and C max , and showed high inter-subject variability. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Lanreotide· 12.3 Pharmacokinetics · cmax auc single dose linearity variability text · Sin... | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | <= 1 day <= 86400 seconds | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Lanreotide· 12.3 Pharmacokinetics · lanreotide repeat dose tmax within first day · Acrome... | Open |
| 2 | <= 1 day <= 86400 seconds | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Route: subcutaneous · Lanreotide· 12.3 Pharmacokinetics · lanreotide single dose tmax within first day · After... | Open |
Interpretation: Exposure and absorption values should be compared only within matching route, dose, matrix, population, and unit context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Distribution volume, plasma protein binding, permeability, and BBB penetration evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 16.1 L | Comparable | UK eMC SmPC section 5.2 pharmacokinetics manual extraction · human · serum | Route: intravenous · Dose/window: healthy volunteers after intravenous administration · Time: steady state | Open |
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | 79-83 % | Comparable | Health Canada SBD 3.3.2 pharmacokinetics manual extraction · human · serum | Dose/window: lanreotide 12-60 ng/mL | Open |
PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.
artificial membrane
cell monolayer
cell monolayer
cell monolayer
barrier evidence
Interpretation: Distribution, protein binding, PAMPA, cell-monolayer, and BBB evidence are not interchangeable without matching assay/model context.
Reviewed observations retained without being collapsed into comparable values.
Endpoints define the scientific questions in this domain; the measurements below carry the values and assay context.
Clearance and half-life evidence.
The same three research-facing layers are used across ADMETatlas.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
| # | Value | Evidence layer | Assay / model | Condition | Reference |
|---|---|---|---|---|---|
| 1 | Observation Age has no effect on clearance of lanreotide based on population PK analysis in patients with GEP-NET which included 122 patients aged 65 to 85 years with neuroendocrine tumors. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Lanreotide· 12.3 Pharmacokinetics · lanreotide age no clearance effect text · Age has no... | Open |
| 2 | Observation The effect of hepatic impairment on clearance of lanreotide has not been studied in patients with GEP-NET. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Lanreotide· 12.3 Pharmacokinetics · lanreotide hepatic impairment clearance not studied t... | Open |
| 3 | Observation In subjects with moderate to severe hepatic impairment, a 30% reduction in clearance of lanreotide was observed. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Lanreotide· 12.3 Pharmacokinetics · lanreotide hepatic impairment clearance reduction tex... | Open |
| 4 | Observation Mild (CLcr 60-89 mL/min) or moderate (CLcr 30-59 mL/min) renal impairment has no effect on clearance of lanreotide in patients with GEP-NET based on population PK analysis which included 106 patients with mild and 59 patients with moderate renal impairment treated with SOMATULINE DEPOT. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human | Lanreotide· 12.3 Pharmacokinetics · lanreotide renal impairment no clearance effect text... | Open |
| 5 | Observation An approximate 2-fold decrease in total serum clearance of lanreotide, with a consequent 2-fold increase in half-life and AUC was observed. | Reported | DailyMed SPL 12.3 Pharmacokinetics label extraction · human · serum | Lanreotide· 12.3 Pharmacokinetics · lanreotide renal impairment clearance auc change text... | Open |
Interpretation: Clearance and half-life require route, matrix, species/population, and time-scale context before comparison.
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
The identity reference does not expose a sequence string.
No reported sequence notation is available in the current identity references.
No sequence representation
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
Reference link | ExposurePersistence Area Under Curve, Bioavailability, Clearance, Max Concentration +1 more | No reported alias | 0 identity 17 evidence |
Reference link | Distribution Plasma Protein Binding | No reported alias | 1 identity 1 evidence |
Reference link | Distribution Volume Of Distribution | No reported alias | 0 identity 1 evidence |
Reference link | Exposure Bioavailability | No reported alias | 0 identity 1 evidence |
Interpretation: Reference links and reported notations help confirm that measurements point to the same peptide identity or a compatible peptidoform. ADMET interpretation still belongs to the endpoint modules above, where assay/model and condition context are shown with each measurement.
Identity, sequence, profile-level fields, and current release view metadata.
Endpoint-level measurements attached to this peptide, suitable for review or reanalysis.
Nested peptide record for scripted retrieval, including identity and evidence context.
The request returns the same structured peptide record used by this profile. Measurement downloads use the same peptide identifier and public release visibility.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0027686' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Interpretation: Use these files as the reproducible data package for this peptide profile. Cross-peptide comparison still depends on compatible endpoints, assays, species or model systems, route, dose, matrix, and evidence layer.